Abstract 87P
Background
Glioblastoma is the most common and aggressive primary brain cancer with an overall survival of 15 months despite aggressive cytotoxic treatments. Therefore, identifying new therapeutic targets within the tumor microenvironment (TME) is critical for improving patient outcomes. In glioblastoma, macrophages make up to 30% of the bulk tumor, which include both yolk-sac derived tissue-resident microglia and monocyte-derived macrophages (MDMs) that are recruited from the bone marrow during inflammation. During hematopoiesis, MDMs can arise from granulocyte-monocyte progenitors (GMPs) or monocyte-dendritic cell progenitors (MDPs), which give rise to neutrophil-like or dendritic cell-like lineages, respectively. Although MDMs as a whole are often considered tumor-promoting, the functional role of specific MDM ontogenies is not known. Our recent study identified a subset of MPO+ MDMs associated with better overall survival, enhanced cytotoxic function, and gene expression suggestive of a GMP origin. Therefore, the aim of this study is to characterize the role of MDM ontogeny in brain tumor progression.
Methods
Using a combination of RNA-sequencing, in vitro functional assays and in vivo fate-mapping tools, we assessed the functional role of macrophage ontogeny in glioblastoma models. Additionally, we adoptively transferred monocytes cultured ex vivo from distinct developmental origins to trace their recruitment to tumors and assess the subsequent impact on tumor growth.
Results
Interestingly, macrophage ontogeny was associated with differences in MHC I-mediated and MHC II-mediated antigen presentation as well as unique profile of cytokines and chemokines, including MPO. Additionally, we found differences in phagocytosis towards glioma cells and upregulation of different inflammatory pathways. Importantly, adoptive transfer of monocytes of distinct ontogenies had opposing effects on brain tumor progression and resulted in significant changes to the TME and peripheral immune system.
Conclusions
Our findings shed light on the developmental origins of brain tumor MDMs and their putative regulatory impact in the TME.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Brain Tumour Foundation of Canada.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
158P - Enhancing the communication of genomic results: Understanding patient and clinician perspectives
Presenter: Eleanor Johnston
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - CICLADES-CE study: Genomic signatures detected in DNA from FFPE samples of patients with advanced or metastatic breast cancers treated with anti-aromatase and CDK4/6 inhibitors
Presenter: Margaux BETZ
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - PDL1 expression and its relation to EML4-ALK gene variants in metastatic lung adenocarcinoma: A single-center real-world experience
Presenter: Santhosh Meedimale
Session: Cocktail & Poster Display session
Resources:
Abstract
163P - Impact of genomic sequencing data on treatment decisions in advanced breast cancer (ABC)
Presenter: Sviatoslav Chekhun
Session: Cocktail & Poster Display session
Resources:
Abstract
164P - Clinical utility of comprehensive molecular profiling tests for advanced gastrointestinal tumors
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
165P - Evaluation of the mutational profile in patients with metastatic non-small cell lung carcinoma diagnosed in a tertiary hospital which was performed by NGS method
Presenter: Kankan Deka
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Targeted next-generation sequencing as reliable detection of genetic profile for cancer treatment to guide oncologists in Pakistan
Presenter: Zeeshan Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Molecular analysis of gastrointestinal stromal tumor (GIST): The experience of Regina Elena National Cancer Institute
Presenter: Andrea Torchia
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Usefulness of liquid biopsy in the management of patients with advanced or metastatic pancreatic cancer
Presenter: Jorge Iranzo Barreira
Session: Cocktail & Poster Display session
Resources:
Abstract